T

he pharmaceutical company Mylan has developed a reputation for fighting tooth-and-nail to promote its flagship product, the EpiPen.

Mylan has contended that its intensive marketing efforts save lives. But over the past year, the public has started to question whether the company’s business tactics are in line with the best interests of patients.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X